Related Experiment Video
Updated: May 2, 2026

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
Published on: January 31, 2020
Segmental vitiligo after infliximab use for rheumatoid arthritis--a case report
Clarissa Luiza Dalla Bernardina Carvalho1, Luciena Cegatto Martins Ortigosa2
1Universidade do Oeste Paulista, Hospital Regional de Presidente Prudente, Presidente PrudenteSP, Brazil, MD, resident in Dermatology at Hospital Regional de Presidente Prudente - Universidade do Oeste Paulista (HRPP- UNOESTE) - Presidente Prudente (SP), Brazil.
Abstract:
The tumor necrosis factor alpha is a cytokine related to immune and inflammatory processes by acting on different parts of the body. It is secreted by several cell types including macrophages, lymphocytes, monocytes, neutrophils, dendritic cells, among others. Infliximab is a chimeric monoclonal antibody that specifically binds to soluble and transmembrane tumor necrosis factor alpha form blocking its action. In rheumatoid arthritis it is used because the cytokines that cause inflammation in this disease are regulated by tumor necrosis factor alpha and IL-1. We report the case of a 46-year-old patient with rheumatoid arthritis who developed segmental vitiligo after two months using infliximab. The event aims to alert to the existence of this adverse effect that can be induced with the use of this medication.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease III: Crohn's Disease
Inflammatory Bowel Disease IV: Clinical Manifestations
Inflammatory Bowel Disease II: Ulcerative Colitis

